Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven primary or metastatic malignant supratentorial anaplastic glioma
• * Newly diagnosed or recurrent
• * No diffusely infiltrating or multifocal tumor
• * No tumor with subependymal spread
• Resection of glioma and placement of an intralesional catheter into the surgical cavity required before study
• Measurable lesion on enhanced CT scan or MRI
• * No measurable enhancing lesion greater than 1.0 cm beyond cavity margin
• Neoplastic cell reactivity with tenascin demonstrated by immunohistology with either a polyclonal rabbit antibody or a monoclonal murine antibody
• PATIENT CHARACTERISTICS:
• Age:
• 3 and over
• Performance status:
• Karnofsky 50-100%
• Hematopoietic:
• Absolute neutrophil count greater than 1,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hepatic:
• Bilirubin less than 1.5 mg/dL
• AST less than 1.5 times normal
• Alkaline phosphatase less than 1.5 times normal
• Renal:
• Creatinine less than 1.2 mg/dL
• Other:
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• At least 6 weeks since prior chemotherapy unless unequivocal evidence of tumor progression
• Endocrine therapy:
• Corticosteroids allowed if at lowest possible dose and dose stable for at least 10 days prior to entry
• Radiotherapy:
• At least 3 months since prior radiotherapy to site of measurable disease unless unequivocal evidence of tumor progression
• Surgery:
• See Disease Characteristics